---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-077377"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T11:32:35.683272+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexeo raises $80M in private placement; cash runway into 2028

## Summary
- Gross proceeds ~$80M from sale of 20.79M shares and warrants at $2.8825/unit.
- Pre-funded warrants for 6.96M shares at $0.0001; common warrants expire May 28, 2029.
- Financing co-led by Frazier Life Sciences and Janus Henderson; J.P. Morgan, Oppenheimer placement agents.
- Proceeds to fund clinical programs including LX2006 efficacy readout expected by 2027.
- Private placement expected to close May 28, 2025; resale registration to be filed by June 27, 2025.

## SEC filing metadata
- accession: 0000950170-25-077377
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/0000950170-25-077377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/lxeo-20250527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-077377
- JSON: https://secwatch.observer/filing/0000950170-25-077377.json
- Plain text: https://secwatch.observer/filing/0000950170-25-077377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.